MediWound COO sells 5,823 shares after option exercise
Rhea-AI Filing Summary
MediWound Ltd. (MDWD) reported insider option exercises and share sales by Shmuel Hess, COO & Chief Commercial Officer. On August 26–27, 2026 he exercised 16,000 stock options at an exercise price of $8.1292 per share on a net (cashless) basis, receiving 5,823 ordinary shares that were all sold the same days in open-market transactions totaling 5,823 shares at prices between $12.72 and $13.126 per share. He continues to hold several option grants over additional ordinary shares with exercise prices between $12.729 and $18.54 and expirations from 2034 to 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
11 txns
Insider
Hess Shmuel
Role
COO & Chief Commercial Officer
Sold
5,823 shs ($75K)
Approx. gross sale proceeds
$75K
Approx. exercise cost
$130K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy ordinary shares) F4, F9 | 11,000 | $0.00 | $0.00 |
| Sale | Ordinary Shares F9 | 1,979 | $12.72 | $25K |
| Sale | Ordinary Shares F9 | 1,979 | $13.126 | $26K |
| Exercise | Stock Option (right to buy ordinary shares) F4, F8 | 5,000 | $0.00 | $0.00 |
| Sale | Ordinary Shares F8 | 1,865 | $13.00 | $24K |
| holding | Stock Option (right to buy ordinary shares) F5, F10 | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) F6, F10 | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) F7, F10 | -- | -- | -- |
| holding | Ordinary Shares F1, F10 | -- | -- | -- |
| holding | Ordinary Shares F2, F10 | -- | -- | -- |
| holding | Ordinary Shares F3, F10 | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 103,681 shares (Direct);
Ordinary Shares — 10,085 shares (Direct)
Footnotes (10)
- F1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F4. The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F5. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F6. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F7. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F8. The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.
- F9. The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.
- F10. There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only.
Key Figures
Options exercised (first tranche): 5,000 stock options
Options exercised (second tranche): 11,000 stock options
Exercise price: $8.1292 per share
+5 more
8 metrics
Options exercised (first tranche)
5,000 stock options
Exercised on a net (cashless) basis on August 26, 2026
Options exercised (second tranche)
11,000 stock options
Exercised on a net (cashless) basis on August 27, 2026
Exercise price
$8.1292 per share
Exercise or conversion price for the 5,000 and 11,000 options
Shares sold total
5,823 ordinary shares
Aggregate shares sold in open-market transactions on August 26–27, 2026
Sale prices
$12.72–$13.126 per share
Per-share prices for open-market sales of ordinary shares
Remaining options (2034 expiration)
32,681 underlying ordinary shares
Stock option grant at $12.729 exercise price expiring February 26, 2034
Remaining options (2035 expiration)
24,000 underlying ordinary shares
Stock option grant at $18.54 exercise price expiring February 11, 2035
Remaining options (2036 expiration)
31,000 underlying ordinary shares
Stock option grant at $17.60 exercise price expiring March 4, 2036
Key Terms
net (cashless) basis, restricted share units ("RSUs"), exercise price, vest equally on a quarterly basis, +1 more
5 terms
net (cashless) basis financial
"The Reporting Person exercised 5,000 stock options on a net (cashless) basis."
exercise price financial
"Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest equally on a quarterly basis financial
"an additional 6.25% of the RSUs vest equally on a quarterly basis"
expiration date financial
"expiration_date": "2035-02-11""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transactions did MDWD executive Shmuel Hess report on this Form 4?
Shmuel Hess reported exercising 16,000 stock options on a net (cashless) basis and selling all 5,823 ordinary shares received in open-market transactions on August 26–27, 2026 at prices between $12.72 and $13.126 per share.
How many MediWound (MDWD) options did Shmuel Hess exercise and at what price?
He exercised a total of 16,000 stock options, comprising 5,000 options and 11,000 options, each with an $8.1292 exercise price per ordinary share, using a net (cashless) exercise method as described in the footnotes.
Were the MediWound (MDWD) option exercises by Shmuel Hess cashless?
Yes. The footnotes state that 5,000 and 11,000 stock options were exercised on a net (cashless) basis, with shares otherwise issuable upon exercise withheld to satisfy the aggregate exercise price, and all net shares issued then sold the same days.
What MDWD equity awards does Shmuel Hess continue to hold after these transactions?
He continues to hold stock options over 32,681, 24,000, and 31,000 underlying ordinary shares with exercise prices of $12.729, $18.54, and $17.60, expiring on February 26, 2034, February 11, 2035, and March 4, 2036, respectively.
Does the MDWD Form 4 mention any RSU holdings for Shmuel Hess?
Yes. Footnotes describe ordinary shares underlying RSUs granted on February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% after one year and 6.25% quarterly over three additional years, but no transactions occurred in those RSUs.
AI-generated analysis. How Rhea-AI works. Not financial advice.
